Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Jun;28(3):275-7.
doi: 10.3341/kjo.2014.28.3.275. Epub 2014 May 19.

Suspected bacterial endophthalmitis following sustained-release dexamethasone intravitreal implant: a case report

Mücella Arıkan Yorgun  1 , Melek Mutlu  1 , Yasin Toklu  1 , Hasan Basri Cakmak  2 , Nurullah Cağıl  2
Affiliations
Case Reports

Suspected bacterial endophthalmitis following sustained-release dexamethasone intravitreal implant: a case report

Mücella Arıkan Yorgun et al. Korean J Ophthalmol. 2014 Jun.

Abstract

A 58-year-old man admitted to our opthalmology department with the complaint of branch retinal vein occlusion. He was treated with intravitreal Ozurdex in the right eye. Two days after the injection, the patient presented with ocular pain and the visual acuity was hand movement. A diagnosis of endophthalmitis was made. We performed emergent pars plana vitrectomy (PPV) and the implant was removed from the vitreous cavity using a retinal forceps. A combination of vancomycin 1.0 mg and amikacin 0.4 mg was injected intravitreally. However, because of the blurring in the vitreus one week after the procedure, phacoemulsification and a repeat PPV was performed. Five days after the last procedure the signs and symptoms of endophthalmitis were resolved. Our case demonstrated that endophthalmitis could develop after intravitreal implantation of Ozurdex. Surgical removal of the implant and immediate vitrectomy seems to be a useful treatment option in these cases.

Keywords: Dexamethasone implant; Endophthalmitis; Ozurdex; Pars plana vitrectomy.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Significant anterior chamber reaction with hypopyon.
Fig. 2
Fig. 2
The implant was removed from the vitreous cavity using a retinal forceps.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schmitz K, Maier M, Clemens CR, et al. The ZERO study. Reliability and safety of intravitreal Ozurdex injections. Ophthalmologe. 2014;111:44–52. - PubMed
    1. Haller JA, Bandello F, Belfort R, Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453–2460. - PubMed
    1. Marchino T, Vela JI, Bassaganyas F, et al. Acute-onset endophthalmitis caused by alloiococcus otitidis following a dexamethasone intravitreal implant. Case Rep Ophthalmol. 2013;4:37–41. - PMC - PubMed
    1. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28:351–366. - PubMed
    1. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479–1496. - PubMed

Publication types

MeSH terms

LinkOut - more resources